← Back to Search

Stem Cell Therapy

BMAC vs Triamcinolone for Hip Osteoarthritis

Phase 3
Waitlist Available
Led By LEONARDO P OLIVEIRA, MD
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Unilateral or Bilateral Hip Osteoarthritis
Prior physical therapy treatment for 6 weeks in the last 6 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up evaluate the change in pain and functional scores of a single bone marrow aspirate injection in comparison to triamcinolone in patients with hip osteoarthritis through validated patient reported outcomes scores at baseline to 12 months.
Awards & highlights

Study Summary

This trial is testing whether bone marrow aspirate concentrate (BMAC) is more effective than Triamcinolone in reducing pain and improving function in patients with hip osteoarthritis.

Who is the study for?
This trial is for men and women aged 18-65 with hip osteoarthritis, who have had physical therapy but no recent corticosteroid injections or active autoimmune diseases. Participants must not be pregnant, planning pregnancy, or have a history of certain medical conditions like uncontrolled diabetes or thyroid dysfunction.Check my eligibility
What is being tested?
The study compares the effectiveness of bone marrow aspirate concentrate (BMAC) versus Triamcinolone in reducing pain and improving function in hip osteoarthritis patients. It measures outcomes through patient-reported scores and performance on a walking test over 12 months.See study design
What are the potential side effects?
Potential side effects may include discomfort at the injection site, infection risk from needle insertion, allergic reactions to components used during the procedure, and general risks associated with bone marrow aspiration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have arthritis in one or both of my hips.
Select...
I have undergone physical therapy for 6 weeks in the past 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~evaluate the change in pain and functional scores of a single bone marrow aspirate injection in comparison to triamcinolone in patients with hip osteoarthritis through validated patient reported outcomes scores at baseline to 12 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and evaluate the change in pain and functional scores of a single bone marrow aspirate injection in comparison to triamcinolone in patients with hip osteoarthritis through validated patient reported outcomes scores at baseline to 12 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Western Ontario McMaster Universities Arthritis Index (WOMAC)
Secondary outcome measures
6 Minute Walk Test (6MWT)
Other outcome measures
Global Rate of Change (GRoC)
Pain
PROMIS - Physical Function (PROMIS-PF)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bone marrow aspirate concentrateExperimental Treatment1 Intervention
Bone marrow that is aspirated then concentrated using a device.
Group II: TriamcinoloneActive Control1 Intervention
Triamcinolone is a corticosteroid.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Bone Marrow Aspirate Concentrate (BMAC) leverages the regenerative properties of mesenchymal stem cells (MSCs) to potentially repair and regenerate damaged cartilage in Hip Osteoarthritis (OA) patients, addressing the underlying issue of cartilage degradation. Triamcinolone, an anti-inflammatory corticosteroid, reduces inflammation and pain by inhibiting inflammatory mediators, offering immediate symptomatic relief. These treatments are significant for OA patients as BMAC aims for long-term cartilage repair, while Triamcinolone provides quick pain relief, improving overall quality of life.

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,036 Previous Clinical Trials
1,368,893 Total Patients Enrolled
Lisa Dean Moseley FoundationUNKNOWN
LEONARDO P OLIVEIRA, MDPrincipal InvestigatorCleveland Clinic Florida

Media Library

Emcyte PureBMC (Stem Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04990128 — Phase 3
Hip Osteoarthritis Research Study Groups: Bone marrow aspirate concentrate, Triamcinolone
Hip Osteoarthritis Clinical Trial 2023: Emcyte PureBMC Highlights & Side Effects. Trial Name: NCT04990128 — Phase 3
Emcyte PureBMC (Stem Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04990128 — Phase 3
~67 spots leftby Jul 2025